MXPA06000661A - Npcili (npc3) y metodos de uso del mismo. - Google Patents

Npcili (npc3) y metodos de uso del mismo.

Info

Publication number
MXPA06000661A
MXPA06000661A MXPA06000661A MXPA06000661A MXPA06000661A MX PA06000661 A MXPA06000661 A MX PA06000661A MX PA06000661 A MXPA06000661 A MX PA06000661A MX PA06000661 A MXPA06000661 A MX PA06000661A MX PA06000661 A MXPA06000661 A MX PA06000661A
Authority
MX
Mexico
Prior art keywords
npc1l1
methods
npc3
polypeptides
antagonists
Prior art date
Application number
MXPA06000661A
Other languages
English (en)
Inventor
Michael P Graziano
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/621,758 external-priority patent/US20040093629A1/en
Priority claimed from US10/646,301 external-priority patent/US20040137467A1/en
Application filed by Schering Corp filed Critical Schering Corp
Publication of MXPA06000661A publication Critical patent/MXPA06000661A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/0412—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K51/0427—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0444—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0493—Steroids, e.g. cholesterol, testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Environmental Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Animal Husbandry (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)

Abstract

La presente invencion provee polipeptidos y polinucleotidos de NPC1L1 de humano, rata y raton que codifican los polipeptidos; tambien se proveen los metodos para detectar agonistas y antagonistas de NPC1L1; los inhibidores de NPC1L1 se pueden utilizar para inhibir la absorcion de colesterol intestinal en un sujeto.
MXPA06000661A 2003-07-17 2003-12-16 Npcili (npc3) y metodos de uso del mismo. MXPA06000661A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/621,758 US20040093629A1 (en) 2002-07-19 2003-07-17 NPC1L1 (NPC3) and methods of use thereof
US10/646,301 US20040137467A1 (en) 2002-07-19 2003-08-22 NPC1L1 (NPC3) and methods of use thereof
US10/663,208 US20040132058A1 (en) 2002-07-19 2003-09-16 NPC1L1 (NPC3) and methods of use thereof
PCT/US2003/040113 WO2005015988A1 (en) 2003-07-17 2003-12-16 Npc1l1 (npc3) and methods of use thereof

Publications (1)

Publication Number Publication Date
MXPA06000661A true MXPA06000661A (es) 2006-03-30

Family

ID=34199007

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06000661A MXPA06000661A (es) 2003-07-17 2003-12-16 Npcili (npc3) y metodos de uso del mismo.

Country Status (7)

Country Link
US (1) US20040132058A1 (es)
EP (4) EP2348046A1 (es)
JP (2) JP2007523595A (es)
AU (1) AU2003297218A1 (es)
CA (1) CA2532576A1 (es)
MX (1) MXPA06000661A (es)
WO (1) WO2005015988A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135556B2 (en) * 2002-07-19 2006-11-14 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
JP4590417B2 (ja) * 2004-01-16 2010-12-01 メルク・シャープ・エンド・ドーム・コーポレイション Ｎｐｃ１ｌ１（ｎｐｃ３）およびこのリガンドの同定方法
WO2007008541A2 (en) * 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
WO2007100807A2 (en) * 2006-02-24 2007-09-07 Schering Corporation Npc1l1 orthologues
US8116757B2 (en) * 2009-07-29 2012-02-14 Intel Corporation Virtual network service provider for mobile virtual network operator activation
EP2581094A4 (en) * 2010-06-10 2015-04-08 Adbiotech Co Ltd COMPOSITION FOR INHIBITING HYPERLIPIDEMIA AND ADIPOSITAS BY INHIBITING THE INHIBITION OF CHOLESTEROL BY THE DARM

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4568649A (en) 1983-02-22 1986-02-04 Immunex Corporation Immediate ligand detection assay
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US5693489A (en) 1984-03-30 1997-12-02 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
EP0623679B1 (en) 1987-05-21 2003-06-25 Micromet AG Targeted multifunctional proteins
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
CZ14294A3 (en) 1991-07-23 1994-07-13 Schering Corp Substituted beta-lactam compounds usable as hypocholesterol pharmaceutical preparations and process for preparing thereof
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
LT3595B (en) 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5627176A (en) 1994-03-25 1997-05-06 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US5624920A (en) 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
US5756470A (en) 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US6207822B1 (en) 1998-12-07 2001-03-27 Schering Corporation Process for the synthesis of azetidinones
WO2000063703A1 (en) * 1999-04-16 2000-10-26 Schering Corporation Use of azetidinone compounds
AU2001242750A1 (en) * 2000-03-24 2001-10-03 Takeda Chemical Industries Ltd. Novel protein, process for producing the same and use thereof
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
CN1275949C (zh) 2001-03-28 2006-09-20 先灵公司 2－吖丁啶酮中间体化合物的对映体选择性合成
US20040093629A1 (en) * 2002-07-19 2004-05-13 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
JP4590417B2 (ja) * 2004-01-16 2010-12-01 メルク・シャープ・エンド・ドーム・コーポレイション Ｎｐｃ１ｌ１（ｎｐｃ３）およびこのリガンドの同定方法

Also Published As

Publication number Publication date
EP1648223A4 (en) 2008-02-27
EP2322548A1 (en) 2011-05-18
WO2005015988A1 (en) 2005-02-24
JP2010252798A (ja) 2010-11-11
CA2532576A1 (en) 2005-02-24
EP2348046A1 (en) 2011-07-27
US20040132058A1 (en) 2004-07-08
JP2007523595A (ja) 2007-08-23
EP2345669A1 (en) 2011-07-20
AU2003297218A1 (en) 2005-03-07
EP1648223A1 (en) 2006-04-26

Similar Documents

Publication Publication Date Title
SG116667A1 (en) Internal riser inspection system, apparatus and methods of using same.
MX2007006830A (es) Porciones de la familia del polipeptido pancreatico, polipeptidos y metodos que comprenden las mismas.
WO2005047860A3 (en) Antibodies to alpha-synuclein
EP1845735A4 (en) CODING PROCESS FOR MOBILE PICTURES AND DEVICE AND COMPUTER PROGRAM THEREWITH
SG107650A1 (en) Devices and methods for analyte concentration determination
MXPA05012883A (es) Nuevos antagonistas del receptor p2x7 y su uso.
IL166788A (en) Procedure for jammer detection
GB0316943D0 (en) Methods and systems for the annotation of biomolecule patterns in chromatography/mass-spectrometry analysis
IL176223A0 (en) The glucagon-like peptide-1 receptor agonists, the preparation and the use of the same
EP1853598A4 (en) CHEMICAL PROBE COMPOUNDS BECOMING FLUORESCENT AT THEIR REDUCTION, AND METHODS OF USE THEREOF
SG115601A1 (en) Transporting mechanism, movable probe card transporting apparatus using transporting mechanism, and prober
EP1838730A4 (en) PAN-HER ANTAGONISTS AND METHODS OF USE
GB2395281B (en) Test probe
MY133625A (en) Peptide deformylase inhibitors
WO2004009772A3 (en) Npc1l1 (npc3) and methods of use thereof
ITTO20020117A0 (it) Apparecchiatura per prove tribologiche.
MXPA06000661A (es) Npcili (npc3) y metodos de uso del mismo.
TW590264U (en) Portable computer apparatus
EA200700949A1 (ru) Фармацевтические композиции, основанные на антагонистах nk2, для применения в педиатрической практике
EP1491875A4 (en) ANALYSIS DEVICE AND ANALYSIS DISC FOR THIS USE
EP1780274A4 (en) QUANTITATIVE DETECTION / DETERMINATION PROBE OF NITROGEN MONOXIDE, AND METHOD OF QUANTITATIVE DETECTION / DETERMINATION OF NITROGEN MONOXIDE USING THE SAME
WO2005116195A3 (de) Methode zur identifizierung von pde5-modulatoren
EP1729137A4 (en) MOVEMENT METHOD, CELL, MEASURING DEVICE USING THE CELL AND MEASURING METHOD
NO20042500L (no) Chemokin-reseptorantagonister og metoder for anvendelse derav
WO2004003133A3 (en) Pain signaling molecules